Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01
Awarded contract base period of US$3.6 million to fund vaccine manufacturing with additional option periods to advance development through Phase 1 trials Submitted up to US$97 million in additional U.S. government funding proposals HALIFAX, Nova Scotia, Oct.
(Financial Post, 2025-10-01T11:20:42Z)